23 Nov 2020 17:37
IN BRIEF: Evgen Pharma Doses First Patient In Lead Candidate Trial
IN BRIEF: Evgen Pharma Doses First Patient In Lead Candidate Trial
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
EVG.L Share News (EVG)
EVG Share
Price
EVG Share
News
EVG Share
Chat
EVG Share
Trades
EVG
Live RNS
EVG Share
Charts
EVG Broker
Ratings
EVG Directors
Deals
EVG Financial
Diary
EVG
Fundamentals
EVG Short
Positions
EVG
Media
EVG.L Information
- There is currently no data for EVG
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Evolution ponders Panmure bid
Thu, 23rd Sep 2010 17:03
Broker and fund manager Evolution Group says that it is considering a bid for AIM-quoted broker Panmure Gordon. Evolution says that a Panmure offer is one of a number of options under consideration. No formal discussions have taken place with Panmure. Evolution says it is waiting to assess Panmure's interim results which will be announced on 29 September. Panmure points out that revenues are skewed towards the second half so the interim figures may not be that informative. The Panmure board argues that its 46.8% shareholder QInvest is supportive of its strategy.
More News
23 Nov 2020 12:22
Evgen doses first patients in 'STAR' respiratory trial
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced on Monday that the first patient had now been enrolled and dosed in the 'STAR' trial of its 'SFX-01' treatment for acute respiratory infections.
Read more11 Nov 2020 15:53
IN BRIEF: Evgen Pharma About To Begin SFX-01 Trial Recruitment
IN BRIEF: Evgen Pharma About To Begin SFX-01 Trial Recruitment
Read more23 Oct 2020 11:49
Evgen gets full approval for SFX-01 trial in Covid-19 patients
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced on Friday that all necessary regulatory approvals had now been received for the 'STAR' trial of SFX-01 treatment for Acute Respiratory Infections.
Read more23 Oct 2020 11:31
Shares In Evgen Pharma Rise On Approval For SFX-01 Trial
Shares In Evgen Pharma Rise On Approval For SFX-01 Trial
Read more23 Oct 2020 10:46
UK WINNERS & LOSERS SUMMARY: Barclays Lifts FTSE's Lenders
UK WINNERS & LOSERS SUMMARY: Barclays Lifts FTSE's Lenders
Read more24 Sep 2020 18:12
UK EXECUTIVE CHANGE SUMMARY: Carr's Names Pelham To Replace CEO Davies
UK EXECUTIVE CHANGE SUMMARY: Carr's Names Pelham To Replace CEO Davies
Read more15 Sep 2020 22:08
UK TRADING UPDATE SUMMARY: Mortgage Advice Bureau Launches Later Life
UK TRADING UPDATE SUMMARY: Mortgage Advice Bureau Launches Later Life
Read more15 Sep 2020 08:41
Evgen Pharma licences technology to Juvenescence
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the licensing of its sulforaphane stabilisation technology in a number of non-pharmaceutical applications to Juvenescence on Tuesday.
Read more9 Jul 2020 16:16
UK Shareholder Meetings Calendar - Next 7 Days
UK Shareholder Meetings Calendar - Next 7 Days
Read more17 Jun 2020 12:01
Evgen's 'SFX-01' to be tested with Covid-19 patients
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced its participation in the recently-notified funding initiative for Covid-19 clinical trials by the medical research charity LifeArc on Wednesday.
Read more17 Jun 2020 10:42
Evgen Pharma Says SFX-01 To Be Evaluated In Covid-19 Trial
Evgen Pharma Says SFX-01 To Be Evaluated In Covid-19 Trial
Read more15 Jun 2020 11:09
UK WINNERS & LOSERS SUMMARY: Bunzl Rises As It Sees Strong First Half
UK WINNERS & LOSERS SUMMARY: Bunzl Rises As It Sees Strong First Half
Read more15 Jun 2020 10:24
Evgen Pharma Loss Slightly Wider On Expenses And Compensation
Evgen Pharma Loss Slightly Wider On Expenses And Compensation
Read more15 Jun 2020 09:51
Losses widen as Evgen Pharma develops SFX-01
(Sharecast News) - Clinical-stage drug development company Evgen Pharma reported a slight widening of its post-tax loss in its final results on Monday, to £2.7m, from £2.6m in the prior year.
Read more